Early Adcetris OK no surprise to SGEN after taking US FDA's advice
This article was originally published in Scrip
The US FDA has been on a roll this month with approving cancer drugs ahead of schedule, with the latest being Seattle Genetics' Adcetris (brentuximab vedotin), the first therapy in 34 years available to treat patients with Hodgkin’s lymphoma (HL) – coming 11 days early, triggering a 14.2% jump in the Bothell, Washington-based biotech's stock on 19 August.
You may also be interested in...
Takeda/Seattle Genetics announced positive Phase III data from the ALCANZA trial evaluating the antibody drug-conjugate in patients with cutaneous T-cell lymphoma (CTCL). Phase III studies in other potentially larger lymphoma indications are ongoing.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.